Suryeong Go

Suryeong Go

Auto-generated profile, based on publicly available information

Suryeong Go

Infection Prevention and Control Office, Armed Forces Capital Hospital, Seongnam, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
HSHyung Eun Son
Hyung Eun Son
JRJi Young Ryu
Ji Young Ryu
SGSuryeong Go
Suryeong Go
YYYoungjin Yi
Youngjin Yi
KKKipyo Kim
Kipyo Kim
HCHo Jun Chin
Ho Jun Chin
Hyung Eun Son, Ji Young Ryu, Suryeong Go, Youngjin Yi, Kipyo Kim, Yoon Kyu Oh, Kook-Hwan Oh, Ho Jun Chin. Kidney Research and Clinical Practice 2020;39:70-80. https://doi.org/10.23876/j.krcp.19.103

30 September 2021 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
SGSuryeong Go
Suryeong Go
Sejoong KimSejoong Kim
Sejoong Kim
HSHyung-Eun Son
Hyung-Eun Son
JRJi-Young Ryu
Ji-Young Ryu
HYHuijin Yang
Huijin Yang
SBSeon Ha Baek
Seon Ha Baek
Background: Copeptin is secreted in equimolar amounts as arginine vasopressin, main hormone regulating body fluid homeostasis. A recent study reported a copeptin-based classification of osmoregulatory defects in syndromes of inappropriate antidiuresis that may aid in prediction of therapeutic success. We investigated usefulness of copeptin for differentiating etiologies of hyponatremia and predicting efficacy and safety of hypertonic saline treatment in hyponatremic patients. Methods: We performed a multicenter, prospective cohort study of 100 inpatients with symptomatic hyponatremia (corrected serum sodium [sNa] <= 125 mmol/L) treated with hypertonic saline. Copeptin levels were measured at baseline and 24 hours after treatment initiation, and patients were classified as being below or above median of copeptin at baseline or at 24 hours, respectively. Correlations between target, under correction, and overcorrection rates of sNa within 24 hours/24-48 hours and copeptin levels at baseline/24 hours were analyzed. Results: Mean sNa and median copeptin levels were 117.9 and 16.9 pmol/L, respectively. Ratio of copeptin-to-urine sodium allowed for an improved differentiation among some (insufficient effective circulatory volume), but not all hyponatremia etiologic subgroups. Patients with below-median copeptin levels at baseline achieved a higher target correction rate in 6/24 hours (odds ratio [OR], 2.97; p = 0.02/OR, 6.21; p = 0.006). Patients with below-median copeptin levels 24 hours after treatment showed a higher overcorrection rate in next 24 hours (OR, 18.00, p = 0.02). Conclusion: There is a limited diagnostic utility of copeptin for differential diagnosis of hyponatremia. However, copeptin might be useful for predicting responses to hypertonic saline treatment in hyponatremic patients.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
KKKipyo Kim
Kipyo Kim
SGSuryeong Go
Suryeong Go
HSHyung Eun Son
Hyung Eun Son
JRJi Young Ryu
Ji Young Ryu
HLHajeong Lee
Hajeong Lee
JPJung Hwan Park
Jung Hwan Park
Kim K, et al. J Korean Med Sci. 2020 Jun;35(28):e254. https://doi.org/10.3346/jkms.2020.35.e254

1 January 2021 in Military Medicine
Verified
Journal Article
Closed access
SGSuryeong Go
Suryeong Go
CJChan Young Jeong
Chan Young Jeong
BSBang Sup Shin
Bang Sup Shin
JAJoosuk Ahn
Joosuk Ahn
IOIn Mok Oh
In Mok Oh
HOHong Sang Oh
Hong Sang Oh

30 June 2021 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
KKKipyo Kim
Kipyo Kim
EBEunji Baek
Eunji Baek
SGSuryeong Go
Suryeong Go
HSHyung-Eun Son
Hyung-Eun Son
JRJi-Young Ryu
Ji-Young Ryu
HCHo Jun Chin
Ho Jun Chin
Backgrounds: Recently, alternative surrogate endpoints such as a 30% or 40% decline in estimated glomerular filtration rate (eGFR) or eGFR slope over 2 to 3 years have been proposed for predicting renal outcomes. However, the impact of GFR estimation methods on the accuracy and effectiveness of surrogate markers is unknown. Methods: We retrospectively enrolled participants in health screening programs at three hospitals from 1995 to 2009. We defined two different participant groups as YR1 and YR3, which had available 1-year or 3-year eGFR values along with their baseline eGFR levels. We compared the effectiveness of eGFR percentage change or slope to estimate end-stage renal disease (ESRD) risk according to two estimating equations (modified Modification of Diet in Renal Disease equation [eGFRm] and Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation [eGFRc]) for GFR. Results: In the YR1 and YR3 groups, 9,971 and 10,171 candidates were enrolled and ESRD incidence during follow-up was 0.26% and 0.19%, respectively. The eGFR percentage change was more effective than eGFR slope in estimating ESRD risk, regardless of the method of estimation. A 40% of decline in eGFR was better than 30%, and a 3-year baseline period was better than a 1-year period for prediction accuracy. Although some diagnostic indices from the CKD-EPI equation were better, we found no significant differences in the discriminative ability and hazard ratios for incident ESRD between eGFRc and eGFRm in either eGFR percentage change or eGFR slope. Conclusion: There were no significant differences in the prediction accuracy of GFR percentage change or eGFR slope between eGFRc and eGFRm in the general population.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YHYoung Hoon Hwang
Young Hoon Hwang
DYDoran Yoon
Doran Yoon
SGSuryeong Go
Suryeong Go
JYJoon-Sup Yeom
Joon-Sup Yeom
HOHong Sang Oh
Hong Sang Oh
Hwang YH, et al. J Korean Med Sci. 2024 Oct;39:e314. https://doi.org/10.3346/jkms.2024.39.e314